EN DE
Check 35,000+ stocks against 26 valuation models and 37 quality factors
Data-driven stock valuation

BSF Enterprise Plc (BSFA) fair value: what the stock is really worth

We calculate from audited financials what BSF Enterprise Plc is really worth. The fair value tells you whether the price is too high or too low, the quality score (0 to 100) how solid the business behind it is. 26 models, 37 quality factors, updated daily.

Valuation from Jun 24, 2026. With the latest figures (losses, negative cash flow), a fair value can no longer be calculated.
  1. Fair value above price? Yes
  2. Good quality? No
  3. Add to watchlist

Healthcare · GB · ISIN GB00BHNBDQ51

BE Thin data Jun 24, 2026

BSF Enterprise Plc

BSFA · LSE

Cheap, value-trap riskThe stock looks deeply undervalued, but low quality raises value-trap risk.

✓Fair value £0.0255 · Strongly undervalued (+144.0%)
!Quality 25/100
!Weak Growth (revenue YoY −8.6 %/yr)
!negative free cash flow
!Trails peers (2/7)
!Narrow moat 10/100
!Evidence only low, so the estimate is less certain
Watch BSF Enterprise Plc for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card. Watch for free Pro now: $1 first month

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

£30.82 £0.0060 Fair Value £0.0255 Oct 2020 Sep 2026

White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Jun 24, 2026.

How to read this chart

60‑month range £0.0060 – £30.82 · fair‑value band £0.0170 – £0.0255 · the £0.0105 price screens below the £0.0255 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Jun 24, 2026.

Follow BSF Enterprise in your weekly email

Every Wednesday you see whether BSF Enterprise is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

BSF Enterprise Plc, together with its subsidiaries, develops and commercializes cell-based tissue engineering solutions in the United Kingdom and Hong Kong. The company acquires businesses in the biotechnology, marketing, and e-commerce sectors.

Show more

BSF Enterprise Plc, together with its subsidiaries, develops and commercializes cell-based tissue engineering solutions in the United Kingdom and Hong Kong. The company acquires businesses in the biotechnology, marketing, and e-commerce sectors. It also engages in biotechnology start-up; lab-grown cornea and meat research; and development of skin technology. The company was incorporated in 2018 and is based in London, the United Kingdom.

Stock analysis

BSF Enterprise Plc (BSFA) currently trades at £0.0105, while our model-based Fair Value estimate is £0.0255, implying the stock looks roughly 59.0% undervalued today.

Show more

Valuation

How firm this estimate is: it rests on 4 models at a data quality of 95/100, which puts the evidence level at low.

Scenario range: £0.0170 (bear) to £0.0255 (bull), the price of £0.0105 sits below it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 25/100 (below-average quality), in the Healthcare sector.

Weak Growth: Revenue growth is weak, negative or inconsistent.

BSF Enterprise Plc reported revenue of £52.8K in FY2025 versus £0 in FY2021. Reported net income was −£1.1M in FY2025.

Key figures

Market cap 1.6M GBX · P/S ratio 31.8 · EPS (TTM) £−0.0100 · Return on equity −55.0% · Return on assets (EBIT) −34.6% · Operating margin −5,383% · Revenue (TTM) £51.1K · Revenue growth (YoY) −8.6%.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 38 out of 100 (low confidence).

What moves the price

The share trades about 100% below its 52-week high and 74% above its 52-week low.

For context, the median of 10 Healthcare peers we cover trades at 10% fair-value upside, at 144%, BSFA screens cheaper than that median.

Fair Value models

Bear £0.0170 Fair Value £0.0255 Bull £0.0255
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds. Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Highest evidence
NCAV (Graham) £0.0100 £0.0100 £0.0100 53
All 1 models by family
Asset-Based
NCAV (Graham) £0.0100 £0.0100 £0.0100 53

Open the full fair value analysis →

Notify me when BSFA reaches fair value

Put BSFA on your watchlist. We get in touch as soon as price and fair value meet or the trend turns.

Set up alert →

Quality Score breakdown

Overall quality 25/100

Of which business quality 27 · Market factors (momentum, volatility) 17

Profitability 0
Margins and returns on capital today
Quality Growth 50
Are margins and returns improving?
Cashflow 9
Earnings quality: real cash, not paper profit
Fin. Strength 54
Balance sheet, leverage, solvency risk
Investment 67
Disciplined investing over empire-building
Low Volatility 0
Calm price path (market factor)
Momentum 38
Price trend over the last 3–12 months (market factor)
52W Momentum 0
Distance to the 52-week high (market factor)
Net Issuance 0
Share count: buybacks or dilution?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 0/100
Revenue growth is weak, negative or inconsistent.
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed

Watch BSFA, get fair value alerts →

Compare BSF Enterprise Plc with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Biotechnology · 645 stocks

Beats the industry median on 2/6 measures
Overall it trails its industry peers.
Valuation
Quality Score 25 · Bottom 25%
Fair Value upside +144.0% · Top 25%
Profitability
Return on assets −25.6% · Below median
Growth and dividend
Revenue growth −8.6% · Below median

Valuation Multiplesvs Biotechnology median · lower = cheaper

P/B 0.79× · Cheaper than median
P/S (TTM) 42.07× · Priciest 25%

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)100 · sector 0
FUTURE (revenue growth)0 · sector 0
PAST (return on equity)0 · sector 0
HEALTH (low debt)0 · sector 97
DIVIDEND (yield)0 · sector 23

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Biotechnology stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value
Vertex Pharmaceuticals Incorporated VRTX $526.19 $578.81 +10%
Regeneron Pharmaceuticals, Inc REGN $788.04 $1,275 +62%
argenx SE ARGX $959.49 $918.60 −4%
CSL Limited CSL A$176.95 A$194.65 +10%
Samsung Biologics Co 207940 1,366,000 KRW 1,502,600 KRW +10%
BeOne Medicines AG ONC $360.85 $280.94 −22%
Alnylam Pharmaceuticals, Inc ALNY $255.96 $217.88 −15%
Royalty Pharma plc RPRX $58.21 $19.01 −67%
Celltrion, Inc 068270 177,400 KRW 74,519 KRW −58%
WuXi Biologics (Cayman) Inc 2269 HK$53.00 HK$58.30 +10%

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend Stocks

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names ⭐ Top Rated 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Extrinsic Value Calculator…Calculator with industry benchmark Peter Lynch Fair Value Formula &…Calculator with industry benchmark
Run the numbers yourself: free valuation calculators
DCF CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorFama-French ModelIntrinsic Value
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

BSF Enterprise Plc · Fair Value
£0.0255 +59%Fair Value
Calculator →

Cite: Fair Value Calculator (2026). "BSF Enterprise Plc Fair Value". https://www.fairvalue-calculator.com/stock/BSFA

Frequently asked questions

Is BSF Enterprise Plc (BSFA) overvalued or undervalued?
As of Jun 24, 2026, our model estimates a fair value of £0.0255 versus a price of £0.0105, about +144% upside (undervalued).
What is the fair value of BSFA?
Our model-based fair value for BSF Enterprise Plc is £0.0255 (as of Jun 24, 2026), built from audited fundamentals. The current price: £0.0105.
What is the quality score of BSFA?
BSF Enterprise Plc has a Quality Score of 25/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for BSF Enterprise Plc (BSFA)?
Our model-based price target is the fair value of £0.0255 (as of Jun 24, 2026) from 1 valuation models. Cautious scenario £0.0170, optimistic scenario £0.0255. It is a calculation from audited fundamentals, not an analyst target.
What is the BSF Enterprise Plc stock forecast for 2026?
Our models put fair value at £0.0255, about +144% upside versus a price of £0.0105 (undervalued). Cautious scenario £0.0170, optimistic scenario £0.0255. The calculation is refreshed regularly with new filings.
What is the revenue of BSF Enterprise Plc (BSFA)?
BSF Enterprise Plc reported trailing-twelve-month revenue of about £51.1K (latest available figure, as of Jun 24, 2026).
What is the intrinsic value of BSF Enterprise Plc (BSFA)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For BSF Enterprise Plc it is £0.0255 per share (as of Jun 24, 2026), against a price of £0.0105. It is the blended result of 1 valuation models (cash flow, earnings, asset, dividend).
Is BSF Enterprise Plc stock overvalued or undervalued in 2026?
As of Jun 24, 2026, BSFA trades below its calculated fair value: price £0.0105, fair value £0.0255, a gap of about +144% (undervalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of BSFA?
No. The price is what the market pays today (£0.0105); the fair value is what the company's own numbers justify (£0.0255). For BSF Enterprise Plc the two are £0.0151 per share apart. That gap is exactly why we show both numbers side by side.
How much is BSF Enterprise Plc worth?
The market values BSF Enterprise Plc at about 1.6M GBX (market capitalisation, as of Jun 24, 2026). Per share that is £0.0105; our models calculate a fair value of £0.0255 per share.
What do the bullish and bearish scenarios say about BSFA?
Our models span a range for BSF Enterprise Plc: cautious scenario £0.0170, base £0.0255, optimistic £0.0255 per share (as of Jun 24, 2026, price £0.0105). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of BSF Enterprise Plc (BSFA)?
Balance-sheet figures for BSF Enterprise Plc (as of Jun 24, 2026): return on equity −55.0%. They feed the Quality Score of 25/100, which measures business quality independently of the share price.
How far is BSFA from its 52-week high?
BSF Enterprise Plc trades at £0.0105, about 100% below its 52-week high of £4.68 and 74% above the low of £0.0060 (as of Sep 28, 2026). Distance from the high says nothing about value: that is what the fair value of £0.0255 is for.
Which stocks are comparable to BSF Enterprise Plc?
From the same area (Healthcare) we also value Vertex Pharmaceuticals Incorporated, Regeneron Pharmaceuticals, Inc, argenx SE, CSL Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is BSF Enterprise Plc stock attractive at the current price?
The data as of Jun 24, 2026: price £0.0105, calculated fair value £0.0255 (+144%), Quality Score 25/100, from 1 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of BSFA calculated?
We run BSF Enterprise Plc through 1 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of £0.0255, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 15.9 % above its aggregate fair value. BSF Enterprise Plc currently trades 144 % below its own fair value, and the market average says nothing about that. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of BSF Enterprise Plc (BSFA)?
The closing price on Sep 28, 2026 was £0.0105. Our model-based fair value is £0.0255, about +144% upside (undervalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with BSF Enterprise Plc right now?
The large discount to fair value meets weak quality (25/100). That raises the risk this is a value trap rather than a bargain. The price is below even our cautious bear case (£0.0170). The market is more pessimistic than our downside scenario. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution.

Key figures of BSF Enterprise Plc

How large is the market capitalisation of BSF Enterprise Plc (BSFA)?
The market capitalisation of BSF Enterprise Plc is 1.6M GBX. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of BSF Enterprise Plc (BSFA)?
The price-to-sales ratio of BSF Enterprise Plc is 31.8 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of BSF Enterprise Plc (BSFA)?
Earnings per share at BSF Enterprise Plc are £−0.0100. Earnings per share over the last twelve months: total profit spread across every single share.
What is the return on equity of BSF Enterprise Plc (BSFA)?
The return on equity (ROE) of BSF Enterprise Plc is −55.0% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of BSF Enterprise Plc (BSFA)?
On an EBIT basis the return on assets of BSF Enterprise Plc is −34.6% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of BSF Enterprise Plc (BSFA)?
The operating margin of BSF Enterprise Plc is −5,383% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at BSF Enterprise Plc (BSFA)?
Revenue at BSF Enterprise Plc is growing −8.6% versus a year earlier. How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How much free cash flow does BSF Enterprise Plc (BSFA) generate?
The free cash flow of BSF Enterprise Plc is −1.0M GBX (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net cash does BSF Enterprise Plc (BSFA) hold?
BSF Enterprise Plc holds more cash than debt, 149K GBX net (fiscal year 2025). The company holds more cash than debt, a safety cushion.
Free · no account needed

Watch BSF Enterprise Plc in the live analysis

One click puts BSF Enterprise Plc on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.